The Latest Cardiac and Vascular News
New Analyses of thousands of patients spanning Phase 2 and pooled Phase 3 data demonstrate that NEXLETOL safely and significantly lowers LDL-C compared to placebo in patients with renal impairment or hypertension ANN ARBOR, Mich., April 03, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today presented two new analyses from […]
Guidelines issued jointly by the American Heart Association, American College of Cardiology and Heart Failure Society of America New guidelines recommend the use of SGLT inhibitors for the prevention and treatment of heart failure and highlight the need to improve optimization of medical therapies during hospitalizations THE WOODLANDS, Texas, April 04, […]
– NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or improving throughout the study. At Month 30, median change from baseline in NT-proBNP was -437 pg/mL with 68% of participants observing NT-proBNP levels below their baseline – Serum TTR levels were sustainably […]
Updated Sequential Dosing Data Show Administration of PCSK9 Base Editor Followed by ANGPTL3 Base Editor is Well-Tolerated in NHPs Data to be Presented Today at the American College of Cardiology 71st Annual Scientific Session & Expo CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, a biotechnology company pioneering a new […]
AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of amyloid Sensitivity in those with previously diagnosed cardiac disease was 100% in ATTR and 93% in AL Cardiac uptake was also observed in eleven patients who had not previously been diagnosed with cardiac disease SAN FRANCISCO, April […]
Treatment with mavacamten showed sustained improvement in left ventricular outflow tract (LVOT) gradients, New York Heart Association (NYHA) Class and N-terminal pro brain natriuretic peptide (NT-proBNP) levels At 48 and 84 Weeks, Mavacamten safety was consistent with that seen in the EXPLORER-HCM study Interim results were presented as a late-breaking […]
– Data to Be Presented at 2022 ACC Annual Meeting Demonstrate Valve Disease is More Common in Women in the U.S. – – Other Key Findings Suggest Tricuspid and Mitral Regurgitation Have Highest Prevalence Rates; Severe Mitral Regurgitation Diagnosed More Frequently in Centers Offering Percutaneous Mitral Therapies – ALISO VIEJO, Calif.–(BUSINESS […]
Results presented on April 2nd during a Late Breaking Featured Clinical Research Presentation at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22) Trial achieved primary reversal endpoint in older volunteers Bentracimab was well tolerated in the Phase 2b trial, with no drug-related serious adverse events or thrombotic events reported MALVERN, […]
GENT, Belgium–(BUSINESS WIRE)–FEops today announced that it received authorization from the U.S. Food and Drug Administration (FDA) for FEops HEARTguide™ pre-operative planning of left atrial appendage occlusion (LAAo) with the Abbott’s Amplatzer™ Amulet™ and Boston Scientific’s Watchman FLX™ device*. FEops HEARTguide is a one-in-its-kind cloud-based procedure planning solution in the structural […]
– SLN360 reduced Lp(a) – a key genetic risk factor for heart disease – by up to 98% with reductions of up to 81% persisting at 150 days – Results were simultaneously published in The Journal of the American Medical Association (JAMA) LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), […]
